Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 9, 2010, Pages 347-353

  Bijlsma, Johannes W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Recommendations; Rheumatoid arthritis; Strategies; Treatment

Indexed keywords

ABATACEPT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EUROPE; HUMAN; PRIMARY MEDICAL CARE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; ARTICLE; DRUG COMBINATION; EUROPEAN UNION; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; POLAND; PRACTICE GUIDELINE; STANDARD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DELIVERY OF HEALTH CARE; DRUG THERAPY, COMBINATION; EUROPEAN UNION; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; METHOTREXATE; POLAND; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; RHEUMATOLOGY;

EID: 79952118533     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.965     Document Type: Review

References (11)

1. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007: 370: 1861-1864.
2. VanderHeide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with second-line antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996; 124: 699-707.
3. Verstappen SM, Jacobs JW, VanderVeen MJ, et al. Intensive treatment with methotrexate in early RA: aiming for remission. Computer Assisted Management in Early RA (CAMERA, an open label strategy trial). Ann Rheum Dis. 2007; 66: 1443-1449.
4. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69: 631-637.
5. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010: 69: 964-975.
6. Aletaha D, Neogi T, Silman A, et al. The ACR/EULAR classification and diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis. 2010; 69: E-pub ahead of print.
7. Bijlsma JW, Weinblat ME. Optimal use of MTX: the advantage of tight control. Ann Rheum Dis. 2007; 66: 1409-1410. (Pubitemid 350032644)
8. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007; 1: CD006 356.
9. Hoes JN, Jacobs JW, Boers M, et al. EULAR-evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007; 66: 1560-1567. (Pubitemid 350205441)
10. Ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo controlled study of stopping second-line drugs in RA. Lancet. 1996; 347: 347-352. (Pubitemid 26046101)
11. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007; 146: 406-415. (Pubitemid 351650575)